ArticlePloS one2024

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.

Jolien Van den Bossche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.